Skip to Content

Absorica Side Effects

Generic Name: isotretinoin

Note: This page contains information about the side effects of isotretinoin. Some of the dosage forms included on this document may not apply to the brand name Absorica.

In Summary

Common side effects of Absorica include: cheilitis, epistaxis, hypertriglyceridemia, pruritus, xerosis, decreased hdl cholesterol, increased liver enzymes, increased serum triglycerides, musculoskeletal signs and symptoms, dry nose, xeroderma, and xerostomia. Other side effects include: increased serum cholesterol. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to isotretinoin: oral capsule, oral capsule liquid filled

In addition to its needed effects, some unwanted effects may be caused by isotretinoin (the active ingredient contained in Absorica). In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking isotretinoin:

More common:
  • Bone or joint pain
  • burning, redness, itching, or other signs of eye inflammation
  • difficulty with moving
  • nosebleeds
  • scaling, redness, burning, pain, or other signs of inflammation of the lips
  • skin infection or rash
  • Abdominal or stomach pain (severe)
  • attempts at suicide or thoughts of suicide (usually stops after medicine is stopped)
  • back pain
  • bleeding or inflammation of the gums
  • blurred vision or other changes in vision
  • changes in behavior
  • decreased vision after sunset or before sunrise (sudden or may continue after medicine is stopped)
  • diarrhea (severe)
  • headache (severe or continuing)
  • mental depression
  • nausea and vomiting
  • pain or tenderness of the eyes
  • pain, tenderness, or stiffness in the muscles (long-term treatment)
  • rectal bleeding
  • yellow eyes or skin
Incidence not known:
  • Black, tarry stools
  • bloating
  • bloody cough
  • bloody or cloudy urine
  • bone pain, tenderness, or aching
  • burning or stinging of the skin
  • chest pain
  • confusion
  • constipation
  • convulsions
  • cough or hoarseness
  • dark-colored urine
  • decrease in height
  • difficulty breathing
  • difficulty speaking
  • difficulty swallowing
  • discharge from the eyes
  • dizziness
  • double vision
  • ear pain
  • excessive tearing
  • fainting
  • fast, irregular, pounding, or racing heartbeat or pulse
  • fever with or without chills
  • fractures and/or delayed healing
  • heartburn
  • high blood pressure
  • hives or skin rash
  • inability to move the arms, legs, or facial muscles
  • inability to speak
  • indigestion
  • inflamed tissue from infection
  • irregular yellow patch or lump on the skin
  • irritation
  • joint pain, redness, stiffness, or swelling
  • lack or slowing of normal growth in children
  • loosening of the fingernails
  • loss of appetite
  • loss of bladder control
  • loss or change in hearing
  • muscle cramps, spasms, or weakness
  • pain in the ribs, arms, or legs
  • pain or burning in the throat
  • pain or tenderness around the eyes and cheekbones
  • painful cold sores or blisters on the lips, nose, eyes, or genitals
  • painful or difficult urination
  • pains in the chest, groin, or legs, especially calves of the legs
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • pale skin
  • pinpoint red spots on the skin
  • redness or soreness around the fingernails
  • redness, soreness, or itching skin
  • sensitivity of the eyes to sunlight
  • sneezing
  • sores, ulcers, or white spots on the lips or tongue or inside the mouth
  • stuffy or runny nose
  • sudden loss of consciousness
  • sudden loss of coordination
  • sudden onset of severe acne on the chest and trunk
  • sudden onset of slurred speech
  • swelling of the eyelids, face, lips, hands, lower legs, or feet
  • swollen, painful or tender lymph glands in the neck, armpit, or groin
  • tightness in the chest
  • unusual bleeding or bruising
  • unusual weight gain or loss
  • use of extreme physical or emotional force
  • watery or bloody diarrhea

Minor Side Effects

Some of the side effects that can occur with isotretinoin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Crusting of the skin
  • difficulty in wearing contact lenses (may continue after medicine is stopped)
  • dryness of the eyes (may continue after treatment is stopped)
  • dryness of the mouth or nose
  • dryness or itching of the skin
  • headache (mild)
  • increased sensitivity of the skin to sunlight
  • peeling of the skin on palms of the hands or soles of the feet
  • stomach upset
  • thinning of the hair (may continue after treatment is stopped)
Incidence not known:
  • Abnormal menstruation
  • burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feeling
  • changes in fingernails or toenails
  • continuing ringing or buzzing, or other unexplained noise in the ears
  • dandruff
  • darkening of the skin
  • flushing
  • hair abnormalities
  • hair loss
  • increased hair growth, especially on the face
  • lightening of normal skin color
  • lightening of treated areas of dark skin
  • nervousness
  • oily skin
  • redness of the face
  • severe sunburn
  • skin rash, encrusted, scaly and oozing
  • stomach burning
  • sweating
  • trouble sleeping
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • unusually warm skin of the face
  • voice changes

For Healthcare Professionals

Applies to isotretinoin: compounding powder, oral capsule


In general, many side effects associated with isotretinoin (the active ingredient contained in Absorica) are similar to those associated with very high doses of vitamin A (dryness of the skin and mucous membranes).


Dermatologic side effects have included cheilitis, severe mucosal drying, dry mouth, dry nose, dry skin, acne fulminans, flare of cystic acne, alopecia (persistent in some cases), epistaxis, eruptive xanthomas, erythema multiforme, skin fragility, hair abnormalities (including thinning of the hair), hirsutism, hyperpigmentation and hypopigmentation, infections (including disseminated herpes simplex), nail dystrophy, paronychia, palmoplantar desquamation, photoallergic/photosensitizing reactions, pyogenic granuloma, rash (including facial erythema, seborrhea, and eczema), Stevens-Johnson syndrome, increased sunburn susceptibility, sweating, toxic epidermal necrolysis, urticaria, abnormal wound healing (delayed healing or exuberant granulation tissue with crusting), and pruritus. Keloid formation and pyoderma gangrenosum have been reported.[Ref]

A few patients have experienced keloid formation on the face when isotretinoin was administered in conjunction with dermabrasion. Formation generally occurred between one and four months after dermabrasion. Keloid formation has occurred in patients who had been off isotretinoin for up to six months before dermabrasion was completed. Isotretinoin inhibits collagenase, which may result in accumulation of collagen and the formation of hypertrophic scars and keloids.[Ref]


Metabolic side effects have included hypertriglyceridemia, altered blood sugar levels (including elevated fasting blood sugar), hyperuricemia, decreased serum high-density lipoprotein levels, and elevated lactate dehydrogenase, serum cholesterol, and alkaline phosphatase. An association between isotretinoin (the active ingredient contained in Absorica) and an unmasking of latent autoimmune diabetes has been reported in at least 1 case.[Ref]


Ocular side effects have included corneal opacities, decreased night vision (persistent in some cases), cataracts, color vision disorder, conjunctivitis, blepharitis, keratitis, optic neuritis, eye irritation, photophobia, visual disturbances (including blurred vision), and dry eye syndrome. At least one case of transient myopia has been reported.[Ref]

Dry eye syndrome, blepharitis, and conjunctivitis are due the drying effects of isotretinoin and the destabilization of tear-film caused by alterations in meibomian gland function and structure. They are commonly seen within the first four weeks of therapy and are reversible upon the discontinuation of medication. Bacterial conjunctivitis may also occur due to increased colonization of Staphylococcus aureus in the conjunctival sac.

A case reported that blurred vision and photophobia resolved quickly after stopping therapy, but decreased night vision persisted for several months.[Ref]


Osteophytes generally form in the axial skeleton, especially the cervical spine, of patients receiving long-term therapy. Osteophytes also occur more frequently in patients receiving dosages greater than 2 mg/kg/day. One patient with a previous rhinoplasty experienced bilateral nasal bone osteophytes after five weeks of isotretinoin (the active ingredient contained in Absorica) therapy.

Myalgias and arthralgias that are mild and transient generally do not require discontinuation of therapy. Many patients with myalgias also have small hyperostotic lesions of the spine.

One patient, treated with isotretinoin for promyelocytic leukemia, developed myositis, fever, and pleural effusion that slowly resolved after isotretinoin was discontinued.

Causality for osteoporosis, osteopenia, bone fractures, and delayed healing of bone fractures have not been established, although an effect cannot be ruled out. Longer term effects have not been studied.[Ref]

Musculoskeletal side effects have included skeletal hyperostosis; calcification of tendons and ligaments; premature epiphyseal closure; decreased bone mineral density; musculoskeletal symptoms (sometimes severe) including back pain, myalgia, and arthralgia; transient chest pain; arthritis; tendonitis; other types of bone abnormalities; elevated creatine phosphokinase; and rare postmarketing reports of rhabdomyolysis. Muscular and joint pain, mild to moderate in severity, generally resolved following discontinuation of therapy. Spontaneous reports of osteoporosis, osteopenia, bone fractures, and delayed healing of bone fractures have been reported. At least one case of myositis and several cases of osteophytes have been reported. Rarely, sacroiliitis has been reported.[Ref]


A large retrospective population-based cohort study (n=7195) that analyzed data for isotretinoin (the active ingredient contained in Absorica) users provided no evidence that the use of isotretinoin was associated with an increased risk for depression, suicide, or other psychiatric disorders.

Depression symptoms have been reported to disappear after discontinuation of the drug and reappear when isotretinoin is resumed.[Ref]

Psychiatric side effects have included depression, nervousness, psychosis, aggression, violent behaviors, emotional instability, suicidal ideation, suicide attempts, and suicide.[Ref]


Hematologic side effects have included anemia, increased erythrocyte sedimentation rate, leukopenia, thrombocytopenia, neutropenia, and rare reports of agranulocytosis. Laboratory side effects have included decreases in red blood cell parameters, decreases in white blood cell counts, and elevated platelet counts.[Ref]

Nervous system

Nervous system side effects have included lethargy, headache, dizziness, drowsiness, insomnia, paresthesias, seizures, stroke, syncope, weakness, pseudotumor cerebri, hearing impairment, tinnitus, and Guillain-Barre syndrome. At least one case of cerebral ischemia has been reported.[Ref]

Areflexic tetraparesis necessitating ventilatory support, preceded by symptoms of lethargy, epistaxis, cough, arthralgias, paresthesia of the feet, and influenza-like symptoms (Guillain-Barre syndrome), was reported in two male patients, a 31-year-old man and a 13-year-old boy, after oral isotretinoin therapy. Both patients received IV immunoglobulin (2 g/kg) and were discharge from hospital within three months. Neither patient was rechallenged with oral isotretinoin. First patient continued to use topical isotretinoin gel without any adverse effects.

A 30-year-old male experienced cerebral ischemia coincident with isotretinoin therapy. He had been given oral isotretinoin 45 mg per day for 3 months for treatment of severe acne. A cerebral computed tomography scan revealed hypodensity in the right middle cerebral territory corresponding to cerebral ischemia. No risk factors were determined. Isotretinoin was discontinued on admission and the adverse event resolved.[Ref]


Hepatic side effects have included hepatitis and transient elevations in liver function tests (including AST, ALT, and GGTP).[Ref]


Gastrointestinal side effects have included inflammatory bowel disease, pancreatitis, bleeding and inflammation of the gums, colitis, esophagitis/esophageal ulceration, ileitis, nausea, and other nonspecific gastrointestinal symptoms. Taste disturbances (such as loss of taste), anal fissure, and rectal bleeding have been rarely reported.[Ref]


Other side effects have included edema, fatigue, malaise, flushing, bruising, lymphadenopathy, and weight loss.


Cardiovascular side effects have included palpitation, tachycardia (including atrial tachycardia), vascular thrombotic disease, vasculitis (including Wegener's granulomatosis), and stroke.[Ref]

A 22-year-old male with nodular acne experienced symptomatic heart palpitations of 1 week's duration coincident with isotretinoin therapy. He had undergone 2 complete courses of isotretinoin therapy without sequelae and was 3 weeks into his third course. A 12-lead electrocardiogram (ECG) showed atrial tachycardia at a rate of 127 beats per minute. The patient was discharged in stable condition. He was seen at follow-up visits 2 days, 1 week, and 3 months later and underwent serial ECGs each time that showed a gradual decline in heart rate and an eventual return to normal sinus rhythm.[Ref]


Bronchoconstriction and exacerbation of preexisting asthma may be possibly due to the drying effects of isotretinoin (the active ingredient contained in Absorica) on the tracheobronchial tree. In a couple of cases, the condition resolved following discontinuation of therapy, but reoccurred when therapy was reinstituted.[Ref]

Respiratory side effects have included bronchospasms (with or without a history of asthma), respiratory infection, and voice alteration. Bronchoconstriction and exacerbation of preexisting asthma have been reported in a few patients.[Ref]


Hypersensitivity side effects have included allergic reactions, allergic vasculitis, systemic hypersensitivity, and anaphylactic reactions.


Renal side effects have included glomerulonephritis.


Genitourinary side effects have included abnormal menses, white cells in the urine, proteinuria, hematuria (microscopic or gross), and nonspecific urogenital findings.[Ref]


Immunologic side effects have included a case report of isotretinoin-induced pemphigus.[Ref]


1. Ellis CN, Krach KJ "Uses and complications of isotretinoin therapy." J Am Acad Dermatol 45 (2001): S150-7

2. Meigel WN "How safe is oral isotretinoin?" Dermatology 195 (1997): 22-8

3. Conner CS "Isotretinoin: a reappraisal." Drug Intell Clin Pharm 18 (1984): 308-9

4. Lane PR, Hogan DJ "Granulomatous lesions appearing during isotretinoin therapy." Can Med Assoc J 130 (1984): 550

5. Huston NR, Mules R "Acne fulminans with severe myalgia precipitated by isotretinoin therapy." N Z Med J 98 (1985): 821

6. Rubenstein R, Roenigk HH, Jr Stegman SJ, Hanke CW "Atypical keloids after dermabrasion of patients taking isotretinoin." J Am Acad Dermatol 15 (1986): 280-5

7. Elpern DJ "Atypical pyoderma as a side effect of isotretinoin." J Am Acad Dermatol 13 (1985): 1045-6

8. Burke H, Carmichael AJ "Reversible melasma associated with isotretinoin." Br J Dermatol 135 (1996): 862

9. McLane J "Analysis of common side effects of isotretinoin." J Am Acad Dermatol 45 (2001): S188-94

10. Auffret N, Bruley C, Brunetiere RA, Decot MC, Binet O "Photoaggravated allergic reaction to isotretinoin." J Am Acad Dermatol 23 (1990): 321-2

11. Graham BS "Mucosal denudation of the lips from isotretinoin therapy." Arch Dermatol 135 (1999): 349-50

12. Robertson DB, Kubiak E, Gomez EC "Excess granulation tissue responses associated with isotretinoin therapy." Br J Dermatol 111 (1984): 689-94

13. Erpolat S, Gorpelioglu C, Sarifakioglu E "Isotretinoin associated anal fissure and rectal bleeding: a rare complication." Int J Dermatol 51 (2012): 358-9

14. Perry MD, McEvoy GK "Isotretinoin: new therapy for severe acne." Clin Pharm 2 (1983): 12-9

15. Katz BE, Macfarlane DF "Atypical facial scarring after isotretinoin therapy in a patient with previous dermabrasion." J Am Acad Dermatol 30 (1994): 852-3

16. Bigby M, Stern RS "Adverse reactions to isotretinoin. A report from the Adverse Drug Reaction Reporting System." J Am Acad Dermatol 18 (1988): 543-52

17. Goulden V, Layton AM, Cunliffe WJ "Long-term safety of isotretinoin as a treatment for acne vulgaris." Br J Dermatol 131 (1994): 360-3

18. McCormack LS, Turner ML "Photosensitivity and isotretinoin therapy." J Am Acad Dermatol 9 (1983): 273-4

19. Ward A, Brogden RN, Heel RC, Speight TM, Avery GS "Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders." Drugs 28 (1984): 6-37

20. "Product Information. Accutane (isotretinoin)." Roche Laboratories, Nutley, NJ.

21. Ferguson J, Johnson BE "Retinoid associated phototoxicity and photosensitivity." Pharmacol Ther 40 (1989): 123-35

22. Tinoco MP, Tamler C, Maciel G, Soares D, Avelleira JC, Azulay D "Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic." Int J Dermatol 47 (2008): 953-6

23. Rodondi N, Darioli R, Ramelet AA, et al. "High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study." Ann Intern Med 136 (2002): 582-9

24. Neele AM, Buytenhek R, Wallnofer AE, Vangriensven JMT, Kooistra T, Princen HMG "Effects of oral isotretinoin (13-cis retinoic acid) on lipoprotein (a) and apolipoproteins in healthy volunteers." Eur J Clin Nutr 50 ( Suppl (1996): s72

25. Maclean H, Wright M, Choi D, Tidman MJ "Abnormal night vision with isotretinoin therapy for acne." Clin Exp Dermatol 20 (1995): 86

26. Weiss J, Degnan M, Leupold R, Lumpkin LR "Bilateral corneal opacities. Occurrence in a patient treated with oral isotretinoin." Arch Dermatol 117 (1981): 182-3

27. Egger S, Huberspitzy V, Bohler K, Raff M, Scholda C, Barisani T, Vecsei VP "Ocular side effects associated with 13-cis-retinoic acid therapy for acne vulgaris: clinical features, alterations of tearfilm and conjunctival flora." Acta Ophthalmol Scand 73 (1995): 355-7

28. Azurdia RM, Sharpe GR "Isotretinoin treatment for acne vulgaris and its cutaneous and ocular side-effects." Br J Dermatol 141 (1999): 947

29. Palestine AG "Transient acute myopia resulting from isotretinoin (accutane) therapy." Ann Ophthalmol 16 (1984): 660,

30. Fraunfelder FT, Fraunfelder FW, Edwards R "Ocular side effects possibly associated with isotretinoin usage." Am J Ophthalmol 132 (2001): 299-305

31. Knitzer RH, Needleman BW "Musculoskeletal syndromes associated with acne." Semin Arthritis Rheum 20 (1991): 247-55

32. Del Campo DV "Strenuous exercise with isotretinoin." J Am Acad Dermatol 11 (1984): 301

33. Whitmore SE "Isotretinoin has yet to be shown to affect bone density." Arch Dermatol 136 (2000): 424

34. Scuderi AJ, Datz FL, Valdivia S, Morton KA "Enthesopathy of the patellar tendon insertion associated with isotretinoin therapy." J Nucl Med 34 (1993): 455-7

35. Pennes DR, Martel W, Ellis CN, Voorhees JJ "Evolution of skeletal hyperostoses caused by 13-cis-retinoic acid therapy." AJR Am J Roentgenol 151 (1988): 967-73

36. DiGiovanna JJ "Isotretinoin effects on bone." J Am Acad Dermatol 45 (2001): S176-82

37. McBurney EI, Rosen DA "Elevated creatine phosphokinase with isotretinoin." J Am Acad Dermatol 10 (1984): 528-9

38. Pehlivan Y, Kisacik B, Sayiner ZA, Onat AM "Inflammatory back pain in patients treated with isotretinoin." J Rheumatol 38 (2011): 2690

39. Miranda N, Oliveira P, Frade MJ, Melo J, Marques MS, Parreira A "Myositis with tretinoin." Lancet 344 (1994): 1096

40. Rodriguez IH, Allegue F "Achilles and suprapatellar tendinitis due to isotretinoin." J Rheumatol 22 (1995): 2009-10

41. Novick NL, Lawson W, Schwartz IS "Bilateral nasal bone osteophytosis associated with short-term oral isotretinoin therapy for cystic acne vulgaris." Am J Med 77 (1984): 736-9

42. Fiallo P, Tagliapietra AG "Severe acute myopathy induced by isotretinoin." Arch Dermatol 132 (1996): 1521-2

43. Carey BM, Parkin GJ, Cunliffe WJ, Pritlove J "Skeletal toxicity with isotretinoin therapy: a clinico-radiological evaluation." Br J Dermatol 119 (1988): 609-14

44. Azoulay L, Blais L, Koren G, Lelorier J, Berard A "Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study." J Clin Psychiatry 69 (2008): 526-32

45. Nightingale SL "New warning for isotretinoin." JAMA 279 (1998): 984

46. Jick SS "Methodological limitations of the study isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide'' - Reply." Arch Dermatol 137 (2001): 1102-3

47. Enders SJ, Enders JM "Isotretinoin and psychiatric illness in adolescents and young adults." Ann Pharmacother 37 (2003): 1124-7

48. Wysowski DK, Pitts M, Beitz J "An analysis of reports of depression and suicide in patients treated with isotretinoin." J Am Acad Dermatol 45 (2001): 515-9

49. Thakrar BT, Robinson NJ "Isotretinoin and the risk of depression." J Clin Psychiatry 70 (2009): 1475; author reply 1475

50. Jick SS, Kremers HM, VasilakisScaramozza C "Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide." Arch Dermatol 136 (2000): 1231-6

51. Adverse Drug Reactions Advisory Committee (ADRAC) and the Adverse Drug Reactions Unit of the TGA "Australian Adverse Drug Reactions Bulletin. Available from: URL:" ([2005 Jun]):

52. Waisman M "Agranulocytosis from isotretinoin." J Am Acad Dermatol 18 (1988): 395-6

53. Valentic JP, Elias AN, Weinstein GD "Hypercalcemia associated with oral isotretinoin in the treatment of severe acne." JAMA 250 (1983): 1899-900

54. Moeller KE, Touma SC "Prolonged thrombocytopenia associated with isotretinoin." Ann Pharmacother 37 (2003): 1622-4

55. Friedman SJ "Leukopenia and neutropenia associated with isotretinoin therapy." Arch Dermatol 123 (1987): 293-5

56. Johnson TM, Rapini RP "Isotretinoin-induced thrombocytopenia." J Am Acad Dermatol 17 (1987): 838-9

57. Laroche ML, Macian-Montoro F, Merle L, Vallat JM "Cerebral ischemia probably related to isotretinoin." Ann Pharmacother 41 (2007): 1073-6

58. Scheinman PL, Peck GL, Rubinow DR, DiGiovanna JJ, Abangan DL, Ravin PD "Acute depression from isotretinoin." J Am Acad Dermatol 22 (1990): 1112-4

59. Pritchard J, Appleton R, Howard R, Hughes RA "Guillain-Barre syndrome seen in users of isotretinoin." BMJ 328 (2004): 1537

60. Byrne A, Hnatko G "Depression associated with isotretinoin therapy." Can J Psychiatry 40 (1995): 567

61. Kemp A, Rogers M, Kamath R "Retinoid-associated hypertriglyceridemia in chronic granulomatous disease." Am J Med 86 (1989): 360-1

62. Popescu CM, Popescu R "Isotretinoin therapy and inflammatory bowel disease." Arch Dermatol 147 (2011): 724-9

63. Sewell JL, Mahadevan U "Of blemishes and bowels: isotretinoin and inflammatory bowel disease." Gastroenterology 138 (2010): 392-4

64. McCarter TL, Chen YK "Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy." Am J Gastroenterol 87 (1992): 1855-8

65. Flynn WJ, Freeman PG, Wickboldt LG "Pancreatitis associated with isotretinoin-induced hypertriglyceridemia." Ann Intern Med 107 (1987): 63

66. Alikhan A, Henderson GP, Becker L, Sciallis GF "Acne treatment and inflammatory bowel disease: what is the evidence?" J Am Acad Dermatol 65 (2011): 650-4

67. Dresden G "Atrial tachycardia associated with isotretinoin use." Arch Dermatol 143 (2007): 1084-5

68. Kapur N, Hughes JR, Rustin MHA "Exacerbation of asthma by isotretinoin." Br J Dermatol 142 (2000): 388-9

69. Fisher DA "Exercise-induced bronchoconstriction related to isotretinoin therapy." J Am Acad Dermatol 13 (1985): 524

70. Sabroe RA, Staughton RCD, Bunker CB "Bronchospasm induced by isotretinoin." BMJ 312 (1996): 886

71. Edwards S, Sonnex C "Urethritis associated with isotretinoin therapy." Acta Derm Venereol 77 (1997): 330

72. Georgala S, Rigopoulos D, Gourgiotou K, Christofidon E "Isotretinoin-induced pemphigus." Acta Derm Venereol 75 (1995): 413

Not all side effects for Absorica may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.